ArticleCase reports in neurology
Anticoagulant Use during Subacute Asymptomatic Cerebral Cavernous Malformation Hemorrhage.
Article in Case reports in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Several cohort analyses and 2 meta-analyses show a lower risk of cerebral cavernous malformation (CCM) hemorrhage in patients taking anti-thrombotics than those without. Most of the reported patients were taking antiplatelet agents rather than anticoagulants, and little is reported on the use of anticoagulation in the setting of an acute CCM hemorrhage. Case Presentation: We present 3 patients from our practice requiring anticoagulation in the setting of CCM hemorrhage. Patient 1 (age: 61 years) was hospitalized with headache and right arm and leg numbness after a COVID-like illness. Imaging demonstrated a right frontal CCM with subacute blood products in addition to sagittal and transverse sinus thrombosis. The patient was initiated on IV heparin and transitioned to Eliquis. While the CCM continued to have bright T1 signal, it did not result in symptoms over the 12 months of anticoagulation. Patient 2 (age: 62 years) had a history of recurrent pulmonary embolism (PE) on apixaban and underwent brain MRI as part of a metastatic work up for cancer. MRI demonstrated a medullary CCM with subacute blood products. Due to high risk of PE recurrence, anticoagulation maintained and subsequent follow-up MRIs over 1 year were stable and the patient remained asymptomatic. Patient 3 (age: 16 years) was admitted for headache and vomiting, found to have hydrocephalus, an unusual diffuse CCM with subacute blood products and initial concern for occlusion of the straight sinus. He was placed on IV heparin for possible sinus thrombosis with clinical and radiographic stability of his hemorrhages. After a ventricular drain was placed, the straight sinus resumed normal size and the original presentation thought to be pseudo-occlusion due to high pressure. Conclusion: The lack of symptoms and radiographic worsening in these 3 CCM patients acutely anticoagulated with presence of subacute CCM blood products supports the theory that CCM hemorrhage may relate to intra-cavernous thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.